OBJECTIVES:

To predict key health outcomes of the PD-(L)1 inhibitors in France over a five-year period in 13 cancer indications.

METHODS:

A model was developed to estimate key health outcomes for patients initiating treatment with anti PD-(L)1 class from 2023 to 2027 in two worlds: one without anti PD-(L)1 treatments, reflecting management before anti PD-(L)1 launch, and one where patients can also be treated with anti PD-(L)1 inhibitors. The two worlds are compared based on patient life years and quality-adjusted life years (QALYs) gained (related to health states and AE utilities). A partitioned survival model was used to estimate key survival outcomes.

Overall survival, progression-free survival curves and utilities were derived from published Phase III clinical trials. The incidence of each cancer type was based on data from French public databases. The proportion of patients undergoing treatment with an anti PD-(L)1 treatment was based on French-specific market shares.

RESULTS:

The model estimated that 237,089 patients would be treated with anti‐PD‐(L)1 across these 13 indications over a five-year time horizon, with a gain of 200 236 life years in overall survival (+40% of relative gain), 133 434 life years in progression-free survival (+40%), and 149 100 QALYs (+37%). Anti‐PD‐(L)1 treatment usage in 1L NSCLC contributes to most of the outcomes in the world with PD-1s, followed by renal cell carcinoma.

CONCLUSIONS:

PD‐(L)1 inhibitors are estimated to result in considerable improvements in life expectancy and quality of life, demonstrating the need to maintain PD‐(L)1 inhibitors’ status as therapeutic innovation now and in the future in a broad range of cancers.